-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$1.2552.44% Upside
Seres Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Seres Therapeutics, Inc.?
Seres Therapeutics, Inc. has been rated by research analysts at Chardan Capital in the past 90 days.